- $125.62m
- -$28.41m
Brief: Kinnate Biopharma Inc. Provides Corporate Update And Highlights Key Upcoming 2022 Milestones
Brief: Kinnate Biopharma Inc Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
Brief: Kinnate Biopharma Announces Addition To Nasdaq Biotechnology Index
Brief: Kinnate Biopharma Posts Q3 Loss Per Share Of $24.7
Stars aligned in favor of M&A activity in biotech industry - Piper Sandler
Brief: Kinnate Biopharma Inc In Collaboration With Guardant Health Announces Initial Findings From BRAF Kinase Alteration Genomic Landscape And Real-World Clinical Outcomes Study
Brief: Kinnate Biopharma Announces Transition Of Chief Scientific Officer
Brief: Kinnate Biopharma Inc. To Present Trial Design For Its Lead RAF Kinase Inhibitor Program At AACR-NCI-EORTC Virtual International Conference
U.S. RESEARCH ROUNDUP-Altice USA, Kinnate Biopharma, Omeros
U.S. RESEARCH ROUNDUP- Altice USA, Kinnate Biopharma, Omeros
Kinnate Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kinnate Biopharma Reports Quarterly Loss Per Share Of $0.49
Brief: Kinnate Biopharma Inc Appoints Helen Sabzevari, Ph.D. To Board
Brief: Kinnate Biopharma Reports FDA Clearance Of IND Application For KIN-2787
Brief: Kinnate Biopharma Closes $35 Mln Series A Financing To Establish A Chinese Joint Venture
Brief: Kinnate Biopharma Announces Departure Of Stephen Kaldor From Board
Brief: Kinnate Biopharma Inc Reports Full Year 2020 Financial Results
Brief: Kinnate Biopharma Announces Its Addition To The Russell 2000® Index
Kinnate Biopharma: Analysts start with 'buy' on promising pipeline, shares rise